conduritol epoxide has been researched along with Idiopathic Parkinson Disease in 6 studies
conduritol epoxide: conduritol C epoxide refers to the (epi & neo)-isomers; structure
conduritol epoxide : An epoxide resulting from the epoxidation of the double bond of a conduritol.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Ruz, C | 1 |
| Alcantud, JL | 1 |
| Vives, F | 1 |
| Arrebola, F | 1 |
| Hardy, J | 1 |
| Lewis, PA | 1 |
| Manzoni, C | 1 |
| Duran, R | 1 |
| Papadopoulos, VE | 1 |
| Nikolopoulou, G | 1 |
| Antoniadou, I | 1 |
| Karachaliou, A | 1 |
| Arianoglou, G | 1 |
| Emmanouilidou, E | 1 |
| Sardi, SP | 1 |
| Stefanis, L | 2 |
| Vekrellis, K | 1 |
| Kuo, CL | 1 |
| Kallemeijn, WW | 1 |
| Lelieveld, LT | 1 |
| Mirzaian, M | 1 |
| Zoutendijk, I | 1 |
| Vardi, A | 1 |
| Futerman, AH | 1 |
| Meijer, AH | 1 |
| Spaink, HP | 1 |
| Overkleeft, HS | 1 |
| Aerts, JMFG | 1 |
| Artola, M | 1 |
| Dermentzaki, G | 1 |
| Dimitriou, E | 1 |
| Xilouri, M | 1 |
| Michelakakis, H | 1 |
| Ginns, EI | 1 |
| Mak, SK | 1 |
| Ko, N | 1 |
| Karlgren, J | 1 |
| Akbarian, S | 1 |
| Chou, VP | 1 |
| Guo, Y | 1 |
| Lim, A | 1 |
| Samuelsson, S | 1 |
| LaMarca, ML | 1 |
| Vazquez-DeRose, J | 1 |
| Manning-Boğ, AB | 1 |
| Yap, TL | 1 |
| Gruschus, JM | 1 |
| Velayati, A | 1 |
| Westbroek, W | 1 |
| Goldin, E | 1 |
| Moaven, N | 1 |
| Sidransky, E | 1 |
| Lee, JC | 1 |
6 other studies available for conduritol epoxide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Seventy-Two-Hour LRRK2 Kinase Activity Inhibition Increases Lysosomal GBA Expression in H4, a Human Neuroglioma Cell Line.
Topics: Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Glioma; Glucosylceramidase; Humans; Inositol; Leucin | 2022 |
Modulation of β-glucocerebrosidase increases α-synuclein secretion and exosome release in mouse models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Brain; Disease Models, Animal; Exosomes; Glucosylceramidase; Humans; Inosi | 2018 |
In vivo inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activity-based protein profiling.
Topics: Animals; beta-Glucosidase; Brain; Cyclohexanols; Disease Models, Animal; Enzyme Assays; Glucosylcera | 2019 |
Loss of β-glucocerebrosidase activity does not affect alpha-synuclein levels or lysosomal function in neuronal cells.
Topics: alpha-Synuclein; Animals; Autophagy; Cell Differentiation; Cell Line; Gaucher Disease; Glucosylceram | 2013 |
Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.
Topics: alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Evoked Potentials, Moto | 2014 |
Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
Topics: alpha-Synuclein; Amino Acid Substitution; Cell Line, Tumor; Enzyme Inhibitors; Gaucher Disease; Gluc | 2011 |